Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia

Sílvia Casas1, Bálint Nagy, Erkki Elonen

  • 1Department of Pathology, Haartman Institute, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.

Leukemia & Lymphoma
|January 24, 2004
PubMed

Insights

Gene expression of HOXA9, DEK, CBL, and CSF1R was analyzed in acute myeloid leukemia (AML) patients. Aberrant expression levels correlated with specific AML subtypes and CD34 antigen status, offering potential diagnostic insights.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Aberrant gene expression of HOXA9, DEK, CBL, and CSF1R is implicated in acute myeloid leukemia (AML) pathogenesis.
  • Understanding these gene expression patterns is crucial for refining AML diagnosis and prognosis.

Purpose of the Study:

  • To quantify the expression levels of HOXA9, DEK, CBL, and CSF1R in adult AML patients.
  • To investigate the correlation between the expression of these genes and key hematologic and clinical parameters in AML.

Main Methods:

  • Quantitative real-time RT-PCR was employed to analyze gene expression in 41 adult AML patients.
  • Expression levels were correlated with patient age, French-American-British (FAB) classification, immunophenotype, and karyotype aberrations.

Main Results:

  • High prevalence of aberrant gene expression observed: DEK (98% overexpression), HOXA9 (78% overexpression, 15% underexpression), CBL (20% overexpression, 20% underexpression), CSF1R (17% overexpression, 42% underexpression).
  • Lower HOXA9 expression was significantly associated with the t(8;21)(q22;q22) karyotype (p < 0.05).
  • CD34-negative bone marrow samples correlated with DEK or HOXA9 overexpression. AML-M2 subtype showed lower CBL, CSF1R, or HOXA9 expression, while AML-M5 subtype exhibited CBL or CSF1R overexpression.

Conclusions:

  • HOXA9, DEK, CBL, and CSF1R exhibit frequent aberrant expression in adult AML.
  • Specific gene expression patterns are linked to distinct AML subtypes (M2, M5) and cytogenetic abnormalities (t(8;21)), suggesting their potential as biomarkers.